Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctionmRNA 3'-UTR AU-rich region binding

NUDT21 KHSRP

5.06e-0429232GO:0035925
GeneOntologyMolecularFunctionchemoattractant activity

ALKBH1 GPNMB

1.75e-0354232GO:0042056
GeneOntologyBiologicalProcesspositive regulation of hematopoietic progenitor cell differentiation

FLT1 NUDT21

4.26e-059232GO:1901534
GeneOntologyBiologicalProcessmembrane lipid metabolic process

PIGB SGMS1 GLB1 CERS3

1.11e-04229234GO:0006643
PathwayREACTOME_SPHINGOLIPID_METABOLISM

SGMS1 GLB1 CERS3

2.83e-0492203MM15086
PathwayWP_METABOLISM_OF_SPHINGOLIPIDS_IN_ER_AND_GOLGI_APPARATUS

SGMS1 CERS3

3.95e-0421202M39459
PathwayWP_SYNTHESIS_OF_CERAMIDES_AND_1DEOXYCERAMIDES

SGMS1 CERS3

4.34e-0422202M45544
PathwayREACTOME_SPHINGOLIPID_METABOLISM

SGMS1 GLB1 CERS3

4.41e-04107203M14857
PathwayWP_SPHINGOLIPID_METABOLISM_OVERVIEW

SGMS1 CERS3

5.63e-0425202MM15931
PathwayWP_SPHINGOLIPID_METABOLISM_INTEGRATED_PATHWAY

SGMS1 CERS3

6.09e-0426202M39784
PathwayWP_SPHINGOLIPID_METABOLISM_INTEGRATED_PATHWAY

SGMS1 CERS3

6.09e-0426202MM15892
PathwayWP_SPHINGOLIPID_METABOLISM_OVERVIEW

SGMS1 CERS3

6.57e-0427202M39863
PathwayREACTOME_SPHINGOLIPID_DE_NOVO_BIOSYNTHESIS

SGMS1 CERS3

6.57e-0427202MM14646
PathwayWP_SPHINGOLIPID_PATHWAY

SGMS1 CERS3

8.12e-0430202M39501
PathwayREACTOME_SPHINGOLIPID_DE_NOVO_BIOSYNTHESIS

SGMS1 CERS3

1.24e-0337202M554
PathwayKEGG_SPHINGOLIPID_METABOLISM

SGMS1 GLB1

1.37e-0339202M15955
Pubmed

Dephosphorylation of the transcriptional cofactor NACA by the PP1A phosphatase enhances cJUN transcriptional activity and osteoblast differentiation.

GLB1 LMO7

5.18e-051525230948508
Pubmed

Enhancer recruitment of transcription repressors RUNX1 and TLE3 by mis-expressed FOXC1 blocks differentiation in acute myeloid leukemia.

MSH6 NUDT21 KHSRP

1.13e-0413125334551306
Pubmed

Transcription factor Ctip2 controls epidermal lipid metabolism and regulates expression of genes involved in sphingolipid biosynthesis during skin development.

SGMS1 CERS3

1.72e-042725223096701
Pubmed

Morphology-based mammalian stem cell tests reveal potential developmental toxicity of donepezil.

SGMS1 CERS3

1.72e-042725225269881
Pubmed

Splicing Regulator p54nrb /Non-POU Domain-Containing Octamer-Binding Protein Enhances Carcinogenesis Through Oncogenic Isoform Switch of MYC Box-Dependent Interacting Protein 1 in Hepatocellular Carcinoma.

GLB1 LMO7

2.43e-043225231815296
Pubmed

Nuclear actin interactome analysis links actin to KAT14 histone acetyl transferase and mRNA splicing.

MSH6 LMO7 NUDT21 KHSRP

4.39e-0450625430890647
Pubmed

Characterization of an exchangeable gene trap using pU-17 carrying a stop codon-beta geo cassette.

SGMS1 GLB1 SLC23A2 POFUT2

5.46e-0453625415840001
Pubmed

Exchangeable gene trap using the Cre/mutated lox system.

SGMS1 GLB1 SLC23A2 POFUT2

5.53e-0453825410512203
Pubmed

SRCAP complex promotes lung cancer progression by reprograming the oncogenic transcription of Hippo-YAP/TAZ signaling pathway.

MSH6 LMO7 NUDT21 KHSRP

5.97e-0454925438280479
Cytoband17q25.1

BTBD17 RHBDF2

8.98e-048125217q25.1
GeneFamilyRhomboid family

RHBDF2 TMEM115

8.46e-0514182926
Drugretinoic acid; Up 200; 1uM; HL60; HT_HG-U133A

GPNMB HIVEP2 RHBDF2 SLC23A2

1.27e-051452341152_UP
DrugPhenoxybenzamine hydrochloride [63-92-3]; Down 200; 11.8uM; PC3; HT_HG-U133A

MSH6 HIVEP2 SGMS1 SLC23A2

2.79e-051772344652_DN
DrugPempidine tartrate [546-48-5]; Up 200; 13uM; HL60; HT_HG-U133A

FLT1 TEX15 RHBDF2 OPN1SW

4.07e-051952342172_UP
DrugKarakoline [39089-30-0]; Up 200; 10.6uM; HL60; HT_HG-U133A

FLT1 HIVEP2 TEX15 RHBDF2

4.40e-051992342203_UP
Drugpentaethylenehexamine

SGMS1 GLB1

6.40e-0512232CID000019990
Drugb-Mo

GLB1 OPN1SW

1.48e-0418232CID011427297
DrugAMPCPR

SGMS1 GLB1 TMEM115

2.07e-04115233CID000446724
Drug(2S,3R,4S,5S,6R)-2-benzyl-6-(hydroxymethyl)oxane-3,4,5-triol

GLB1 POFUT2

2.44e-0423232CID010332525
Drugstacker

FLT1 GLB1

3.13e-0426232CID000092326
Druglacto-N-tetraose

GLB1 POFUT2

4.75e-0432232CID000440993
Druga-em

FLT1 OPN1SW

5.06e-0433232CID004471892
DrugCP094

CUBN POFUT2 GLP1R

5.95e-04165233CID000086322
Drugisoluminol

MSH6 GLB1

7.44e-0440232CID000095014
Drugprochlorperazine dimaleate salt; Up 200; 10uM; HL60; HT_HG-U133A

GPNMB HIVEP2 SGMS1

7.78e-041812332675_UP
DrugToluene

FLT1 HIVEP2 LMO7 SLC23A2 POFUT2

7.81e-04749235ctd:D014050
Drug5'-pCAGT-3'

MSH6 OPN1SW

8.20e-0442232CID000482144
DrugAG-012559 [369370-06-9]; Down 200; 10uM; PC3; HT_HG-U133A

MSH6 RHBDF2 TMEM115

8.82e-041892336920_DN
DrugCalciferol [50-14-6]; Down 200; 10uM; PC3; HT_HG-U133A

LMO7 SLC23A2 KHSRP

9.09e-041912336746_DN
DrugDisulfiram [97-77-8]; Up 200; 13.4uM; PC3; HT_HG-U133A

FLT1 GPNMB KHSRP

9.09e-041912335729_UP
DrugAntimycin A [1397-94-0]; Down 200; 7.2uM; PC3; HT_HG-U133A

HIVEP2 SLC23A2 NUDT21

9.37e-041932332098_DN
DrugNimodipine [66085-59-4]; Up 200; 9.6uM; MCF7; HT_HG-U133A

GPNMB SGMS1 SLC23A2

9.37e-041932335421_UP
DrugButoconazole nitrate [32872-77-1]; Up 200; 8.4uM; MCF7; HT_HG-U133A

HIVEP2 LMO7 POFUT2

9.51e-041942333288_UP
DrugChloropyramine hydrochloride [6170-42-9]; Down 200; 12.2uM; PC3; HT_HG-U133A

NUDT21 GLP1R KHSRP

9.51e-041942334589_DN
DrugGliquidone [33342-05-1]; Up 200; 7.6uM; HL60; HT_HG-U133A

FLT1 RHBDF2 GLP1R

9.51e-041942333126_UP
DrugSulmazole [73384-60-8]; Down 200; 14uM; HL60; HT_HG-U133A

RHBDF2 SLC23A2 GLP1R

9.66e-041952332153_DN
DrugAcacetin [480-44-4]; Up 200; 14uM; HL60; HT_HG-U133A

FLT1 HIVEP2 KHSRP

9.66e-041952332189_UP
DrugMethyldopate hydrochloride [2508-79-4]; Up 200; 14.6uM; HL60; HT_HG-U133A

OPN1SW GLP1R KHSRP

9.66e-041952332940_UP
DrugSpaglumic acid [4910-46-7]; Down 200; 13.2uM; HL60; HT_HG-U133A

GPNMB SGMS1 POFUT2

9.66e-041952332962_DN
DrugGuanethidine sulfate [60-02-6]; Up 200; 13.4uM; MCF7; HT_HG-U133A

GPNMB LMO7 POFUT2

9.80e-041962333171_UP
DrugQuipazine dimaleate salt [4774-24-7]; Up 200; 9uM; MCF7; HT_HG-U133A

SLC23A2 GLP1R KHSRP

9.80e-041962337240_UP
DrugGraveoline [485-61-0]; Down 200; 14.4uM; PC3; HT_HG-U133A

TEX15 LMO7 GLP1R

9.80e-041962333716_DN
DrugFusidic acid sodium salt [751-94-0]; Up 200; 7.4uM; PC3; HT_HG-U133A

FLT1 SLC23A2 GLP1R

9.80e-041962336754_UP
DrugFluphenazine dihydrochloride [146-56-5]; Down 200; 7.8uM; MCF7; HT_HG-U133A

TBC1D31 SLC23A2 POFUT2

9.80e-041962337234_DN
DrugCalciferol [50-14-6]; Up 200; 10uM; HL60; HT_HG-U133A

MSH6 POFUT2 GLP1R

9.80e-041962332442_UP
DrugHydrochlorothiazide [58-93-5]; Up 200; 13.4uM; MCF7; HT_HG-U133A

RHBDF2 SLC23A2 GLP1R

9.80e-041962334970_UP
DrugEstropipate [7280-37-7]; Down 200; 9.2uM; HL60; HT_HG-U133A

SLC23A2 NUDT21 TMEM115

9.80e-041962332506_DN
DrugAminohippuric acid [61-78-9]; Up 200; 20.6uM; MCF7; HT_HG-U133A

SLC23A2 POFUT2 GLP1R

9.80e-041962336453_UP
DrugPimozide [2062-78-4]; Down 200; 8.6uM; MCF7; HT_HG-U133A

SLC23A2 NUDT21 TMEM115

9.80e-041962333178_DN
DrugEstriol [50-27-1]; Up 200; 13.8uM; MCF7; HT_HG-U133A

LMO7 POFUT2 GLP1R

9.80e-041962333563_UP
DrugAmyleine hydrochloride [532-59-2]; Down 200; 14.8uM; PC3; HG-U133A

SLC23A2 POFUT2 KHSRP

9.80e-041962331909_DN
DrugTolnaftate [2398-96-1]; Up 200; 13uM; MCF7; HT_HG-U133A

MSH6 GPNMB SGMS1

9.80e-041962334805_UP
DrugApramycin [37321-09-8]; Up 200; 7.4uM; HL60; HT_HG-U133A

TEX15 POFUT2 GLP1R

9.80e-041962332914_UP
Drugreduced ascorbic acid

GLB1 SLC23A2

9.83e-0446232CID000000608
DrugTalampicillin hydrochloride [39878-70-1]; Up 200; 7.8uM; HL60; HT_HG-U133A

RHBDF2 SLC23A2 GLP1R

9.94e-041972332954_UP
DrugBambuterol hydrochloride [81732-46-9]; Up 200; 10uM; MCF7; HT_HG-U133A

TEX15 GLP1R KHSRP

9.94e-041972337239_UP
DrugLithocholic acid [434-13-9]; Down 200; 10.6uM; MCF7; HT_HG-U133A

GPNMB SLC23A2 GLP1R

9.94e-041972333899_DN
DrugTrimethadione [127-48-0]; Up 200; 28uM; MCF7; HT_HG-U133A

TEX15 GLP1R KHSRP

9.94e-041972334165_UP
DrugCefaclor [70356-03-5]; Down 200; 10.4uM; HL60; HT_HG-U133A

SGMS1 RHBDF2 GLP1R

9.94e-041972332483_DN
DrugSulfamethizole [144-82-1]; Up 200; 14.8uM; MCF7; HT_HG-U133A

SLC23A2 GLP1R KHSRP

9.94e-041972336099_UP
DrugN-Acetyl-L-leucine [1188-21-2]; Down 200; 23uM; PC3; HT_HG-U133A

HIVEP2 RHBDF2 GLP1R

9.94e-041972334622_DN
Drug6-Furfurylaminopurine [525-79-1]; Down 200; 18.6uM; PC3; HT_HG-U133A

TEX15 GLP1R KHSRP

9.94e-041972334477_DN
DrugNaftifine hydrochloride [65473-14-5]; Up 200; 12.4uM; HL60; HT_HG-U133A

RHBDF2 SLC23A2 KHSRP

9.94e-041972332974_UP
DrugNitrarine dihydrochloride [20069-05-0]; Up 200; 10.6uM; HL60; HT_HG-U133A

FLT1 HIVEP2 RHBDF2

9.94e-041972332188_UP
Drug2-propylpentanoic acid; Up 200; 1000uM; PC3; HG-U133A

SGMS1 SLC23A2 POFUT2

9.94e-04197233458_UP
DrugChlorprothixene hydrochloride [6469-93-8]; Up 200; 11.4uM; HL60; HT_HG-U133A

MSH6 HIVEP2 SLC23A2

1.01e-031982331272_UP
DrugPropafenone hydrochloride [34183-22-7]; Down 200; 10.6uM; PC3; HT_HG-U133A

HIVEP2 RHBDF2 NUDT21

1.01e-031982336336_DN
DrugBethanechol chloride [590-63-6]; Up 200; 20.4uM; MCF7; HT_HG-U133A

TEX15 SLC23A2 GLP1R

1.01e-031982333537_UP
DrugNefopam hydrochloride [23327-57-3]; Down 200; 13.8uM; PC3; HT_HG-U133A

TEX15 LMO7 KHSRP

1.01e-031982333730_DN
DrugBetonicine [515-25-3]; Up 200; 25.2uM; PC3; HT_HG-U133A

GPNMB HIVEP2 CUBN

1.01e-031982334301_UP
Drug6-Furfurylaminopurine [525-79-1]; Down 200; 18.6uM; MCF7; HT_HG-U133A

SLC23A2 POFUT2 GLP1R

1.01e-031982336073_DN
DrugDioxybenzone [131-53-3]; Down 200; 16.4uM; MCF7; HT_HG-U133A

HIVEP2 POFUT2 TMEM115

1.01e-031982335699_DN
DrugAvermectin B1 [71751-41-2]; Down 200; 4.8uM; PC3; HT_HG-U133A

RHBDF2 SLC23A2 POFUT2

1.01e-031982335864_DN
DrugHydroquinine hydrobromide hydrate [304695-81-6]; Up 200; 9.4uM; PC3; HT_HG-U133A

FLT1 GPNMB GLP1R

1.01e-031982335789_UP
Drug(+,-)-Octopamine hydrochloride [770-05-8]; Up 200; 21uM; MCF7; HT_HG-U133A

FLT1 HIVEP2 RHBDF2

1.01e-031982335469_UP
DrugPHA-00745360 [351320-33-7]; Up 200; 1uM; PC3; HT_HG-U133A

GPNMB GLP1R KHSRP

1.01e-031982334562_UP
DrugPhenazopyridine hydrochloride [136-40-3]; Up 200; 16uM; HL60; HT_HG-U133A

FLT1 SLC23A2 GLP1R

1.01e-031982332537_UP
DrugIndapamide [26807-65-8]; Up 200; 10.6uM; MCF7; HT_HG-U133A

GPNMB GLP1R KHSRP

1.01e-031982333970_UP
DrugCP-320650-01 [172079-28-6]; Up 200; 1uM; MCF7; HT_HG-U133A

GPNMB TEX15 KHSRP

1.01e-031982333908_UP
DiseaseSchwartz-Jampel Syndrome, Type 1

FLT1 GLB1

8.21e-0516252C4551479
DiseaseSchwartz-Jampel Syndrome

FLT1 GLB1

8.21e-0516252C0036391
DiseaseMelnick-Needles Syndrome

FLT1 GLB1

8.21e-0516252C0025237
DiseaseSpondyloepiphyseal Dysplasia

FLT1 GLB1

8.21e-0516252C0038015
DiseaseSpondyloepiphyseal Dysplasia Tarda, X-Linked

FLT1 GLB1

8.21e-0516252C3541456
DiseaseVan Buchem disease

FLT1 GLB1

9.30e-0517252C0432272
DiseaseDyschondroplasias

FLT1 GLB1

1.17e-0419252C0013366
DiseaseOsteochondrodysplasias

FLT1 GLB1

1.17e-0419252C0029422
DiseaseMultiple Epiphyseal Dysplasia

FLT1 GLB1

1.30e-0420252C0026760
Diseasesuicide behaviour measurement

SLC23A2 POFUT2

6.09e-0443252EFO_0006882
DiseaseAdenocarcinoma of lung (disorder)

MSH6 FLT1 NUDT21

6.89e-04206253C0152013
Diseaseinitial pursuit acceleration

GPNMB LMO7

2.47e-0387252EFO_0008434

Protein segments in the cluster

PeptideGeneStartEntry
AWLYLTRHFPWSPFP

BLACE

96

A4D250
FIPNPFLPGYQWHWV

ALKBH1

101

Q13686
PFPHHPGWRRWNFIY

GPNMB

161

Q14956
FLPRNYLAPAWGAPW

BTBD17

311

A6NE02
YLAPAWGAPWVINNP

BTBD17

316

A6NE02
PWYLPWASSVPQGHV

GLP1R

86

P43220
QTYVPWNFHEPWPGQ

GLB1

81

P16278
SWRQPPWLNQPTGFY

LMO7

1521

Q8WWI1
EGYPWWPCLVYNHPF

MSH6

101

P52701
PWAAPDFWFLNNVGP

DRC1

431

Q96MC2
PFWPENYPHNSNYQW

CUBN

1866

O60494
WNGYPKQPLLPSQYW

CERS3

166

Q8IU89
GNWWRPNFEPPQYPY

NUDT21

146

O43809
YVVPSWLWEPPGYLH

FAM87A

56

P0C7U9
GFSPQAYPAFWAYPW

C3orf56

66

Q8N813
WDGPQYHIAPVWAFY

OPN1SW

21

P03999
QYPPQGWGNTYPQWQ

KHSRP

541

Q92945
HPWHWYFSQGFPVIL

PIGB

306

Q92521
WCQHWFEYFPNPPIN

TBC1D31

526

Q96DN5
LVLPPWGRLYHWQSP

POFUT2

81

Q9Y2G5
WFKVPYPFQWGLPTV

SLC23A2

361

Q9UGH3
AVTPGYLFPPNFWIW

TMEM115

46

Q12893
VQGIVPRSYHWPFPW

SGMS1

381

Q86VZ5
PEVPWVYAPWHQESF

TEX15

2771

Q9BXT5
AYGIPQPTIKWFWHP

FLT1

456

P17948
VHLPAQQPPWWQAHF

HIVEP2

1216

P31629
QQPPWWQAHFPHPFA

HIVEP2

1221

P31629
YPINWPWIEHLTCFP

RHBDF2

826

Q6PJF5